Default Category
-
To Float or Not to Float? (A) (Spanish version)
Alfaro, Laura; Di Tella, Rafael; Vogel, IngridCase HBS-707S08EconomicsOn July 21, 2005 China revalued its decade-long quasi-fixed exchange rate of approximately 8.28 yuan per U.S. dollar by 2.1% to 8.11% and, at the same time, introduced a more market-based exchange rate system. Many analysts and economists were disappointed with what they considered too small a change and called for more flexibility in the U.S. dollar/yuan exchange rate. Modification to China's exchange rate regime had been eagerly anticipated and...Starting at €8.20
-
China: Flotar o no flotar (C) Esquel Group y el Renminbi chino
Alfaro, Laura; Di Tella, Rafael; Vogel, IngridCase HBS-707S10EconomicsEn julio de 2005, China revaluó su moneda en un 2,1% y ajustar su régimen de tipo de cambio hacia un sistema más basado en el mercado. Esquel Group, una gestión familiar, textiles privadas firma especializada en camisas de algodón de alta calidad con su mayoría de base de producción se encuentra en China, estaba entre aquellas empresas que se enfrentan con el reto de hacer frente a la revaluación del yuan y la posibilidad de apreciación futura . ...Starting at €5.74
-
China: Flotar o no Flotar (B) Calendario de cambios relevantes del Renminbi chino
Alfaro, Laura; Di Tella, Rafael; Vogel, Ingrid; Kim, Renee; Russell, WilliamCase HBS-707S11EconomicsEl 21 de julio, 2005, China revaluó su tipo de cambio cuasi-fijo década de duración de aproximadamente 8,28 yuanes por dólar EE.UU. un 2,1% a 8,11% y, al mismo tiempo, introdujo un sistema de tipo de cambio más basado en el mercado. Muchos analistas y economistas se mostraron decepcionados con lo que consideraban un cambio muy pequeño y pidieron una mayor flexibilidad en el tipo de cambio dólar-yuan EE.UU.. Proporciona una línea de tiempo de más ...Starting at €5.74
-
A Managerial Perspective on Clinical Trials
Daemmrich, Arthur A.Case HBS-709033-EEntrepreneurshipThis note describes the history and regulation of clinical trials, managerial challenges related to pharmaceutical product testing, and current debates regarding prescription drug safety. Since clinical testing takes between five and seven years, and consumes up to 70 percent of a drug's total development costs, pharmaceutical and biotechnology leaders need to understand clinical trial management. Likewise, with a growing variety of new product i...Starting at €8.20
-
Arcadia Biosciences: Seeds of Change (Abridged)
Daemmrich, Arthur A.Case HBS-711050-EArcadia Biosciences is seeking to introduce genetically modified rice to China that will lower farmers' costs and generate environmental benefits through reduced greenhouse gas emissions. The case describes challenges facing this small agricultural biotechnology company, notably uneven enforcement of intellectual property in emerging market countries, and uncertainty regarding the provision and market value of carbon credits under international c...Starting at €8.20
-
Arcadia Biosciences: Seeds of Change
Daemmrich, Arthur A.; Reinhardt, Forest L.; Shelman, MaryCase HBS-709019-EArcadia Biosciences is an entrepreneurial California agricultural biotech company seeking to earn carbon credits by modifying commodity crops for use in China and India. Eric Rey, Arcadia's CEO, faced a strategic inflection point in early September, 2008. The company had a plan to share carbon credits allocated by the United Nations Clean Development Mechanism Executive Board to China, for use of Arcadia's rice varieties, since they enabled farme...Starting at €8.20
-
Arcadia Biosciences: Seeds of Change, Teaching Note
Daemmrich, Arthur A.; Reinhardt, Forest L.Teaching Note HBS-711042-ETeaching Note for 709019.Starting at €0.00